Drug delivery
Generic market entry
Medicinal chemistry
Methods of production and synthesis
Personalised medicine/disease biomarkers
Pharmaceutical formulations
Polymorphs
Small molecule pharmaceuticals
Supplementary protection certificates (SPCs)
The pharmaceuticals sector presents a host of opportunities and challenges in the patent field. From new chemical entities to formulations, synthesis and personalised approaches to treatment, there are a multitude of considerations for any product.
Understanding the patent landscape around any product, including Supplementary Protection Certificates (SPCs), loss of exclusivity and portfolio development opportunities are key strategic considerations for our clients. These areas and the pharmaceuticals sector more generally, continue to drive developments in patent law, a sign of the commercial significance of this field.
The pharmaceuticals team
The team at Boult undertakes the full spectrum of patent work across the pharma sector, from drafting and filing new patent applications through to the management of global patent portfolios. We assist with patent landscaping and freedom to operate (FTO) projects as well as offering advice on infringement and due diligence matters. We are experienced in handling SPCs, particularly consideration of SPC strategy and placement.
Our team has strong academic backgrounds in fields such as organic chemistry, medicinal chemistry, biochemistry and immunology. The result of this is technical expertise means we assist clients across the whole pharma sector.
“Working closely with our clients’ development teams allows us real insight into the goals for each program we are involved with. As a result, we are well-placed to help clients achieve these objectives as well as gaining a strong patent position, both in terms of their own IP portfolio and also in relation to third parties.”
MC2 Therapeutics is a commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions. It received its first marketing authorisation in 2020 for Wynzora Cream®, a topical treatment for plaque psoriasis in adults, and have various other products in the pipeline for treating different skin conditions.
Boult has worked with MC2 Therapeutics for many years. We’ve drafted and prosecuted patent applications for MC2 since the early days, providing valuable protection for inventions ranging from key platform formulation technology to exciting clinical applications. We’ve always enjoyed working closely with inventors at MC2 Therapeutics to identify patentable inventions and navigate together the challenges that inevitably come with a large international filing programme.
It’s been a privilege for us to see MC2 Therapeutics grow as a business over the years and to work together to develop the strong patent portfolio it has today, and we’re excited to see what the future holds.
Morten Præstegaard, Chief Operating Officer at MC2 Therapeutics, said: “MC2 Therapeutics has benefitted hugely from its relationship with Boult over the years. We have grown from a small company with a basic understanding of IP to a significant commercial stage pharmaceutical company with a strong patent portfolio, and this would not have been possible without Boult’s support. Boult has been with us from the beginning, and we see them as not just a contractor, but an active partner to our success.”
MC2 Therapeutics is a commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions. It received its first marketing authorisation in 2020 for Wynzora Cream®, a topical treatment for plaque psoriasis in adults, and have various other products in the pipeline for treating different skin conditions.
Boult has worked with MC2 Therapeutics for many years. We’ve drafted and prosecuted patent applications for MC2 since the early days, providing valuable protection for inventions ranging from key platform formulation technology to exciting clinical applications. We’ve always enjoyed working closely with inventors at MC2 Therapeutics to identify patentable inventions and navigate together the challenges that inevitably come with a large international filing programme.
It’s been a privilege for us to see MC2 Therapeutics grow as a business over the years and to work together to develop the strong patent portfolio it has today, and we’re excited to see what the future holds.
Morten Præstegaard, Chief Operating Officer at MC2 Therapeutics, said: “MC2 Therapeutics has benefitted hugely from its relationship with Boult over the years. We have grown from a small company with a basic understanding of IP to a significant commercial stage pharmaceutical company with a strong patent portfolio, and this would not have been possible without Boult’s support. Boult has been with us from the beginning, and we see them as not just a contractor, but an active partner to our success.”
The pharmaceuticals sector presents a host of opportunities and challenges in the patent field. From new chemical entities to formulations, synthesis and personalised approaches to treatment, there are a multitude of considerations for any product.
Understanding the patent landscape around any product, including Supplementary Protection Certificates (SPCs), loss of exclusivity and portfolio development opportunities are key strategic considerations for our clients. These areas and the pharmaceuticals sector more generally, continue to drive developments in patent law, a sign of the commercial significance of this field.
The pharmaceuticals team
The team at Boult undertakes the full spectrum of patent work across the pharma sector, from drafting and filing new patent applications through to the management of global patent portfolios. We assist with patent landscaping and freedom to operate (FTO) projects as well as offering advice on infringement and due diligence matters. We are experienced in handling SPCs, particularly consideration of SPC strategy and placement.
Our team has strong academic backgrounds in fields such as organic chemistry, medicinal chemistry, biochemistry and immunology. The result of this is technical expertise means we assist clients across the whole pharma sector.
What sets us apart
We have repeated success in guiding clients through the patent process from early stage drug discovery, through to candidate and lead nomination, formulation and clinical development.
Pharmaceuticals continues to inform the development of patent law. This continually changing legal landscape brings opportunities as well as risks to developing the strongest possible patent portfolios, and we have the skills and expertise to assist our clients to achieving this goal.
MC2 Therapeutics is a commercial stage pharmaceutical company committed to research in skin biology and development of novel treatment paradigms for people with autoimmune and chronic inflammatory skin conditions. It received its first marketing authorisation in 2020 for Wynzora Cream®, a topical treatment for plaque psoriasis in adults, and have various other products in the pipeline for treating different skin conditions.
Boult has worked with MC2 Therapeutics for many years. We’ve drafted and prosecuted patent applications for MC2 since the early days, providing valuable protection for inventions ranging from key platform formulation technology to exciting clinical applications. We’ve always enjoyed working closely with inventors at MC2 Therapeutics to identify patentable inventions and navigate together the challenges that inevitably come with a large international filing programme.
It’s been a privilege for us to see MC2 Therapeutics grow as a business over the years and to work together to develop the strong patent portfolio it has today, and we’re excited to see what the future holds.
Morten Præstegaard, Chief Operating Officer at MC2 Therapeutics, said: “MC2 Therapeutics has benefitted hugely from its relationship with Boult over the years. We have grown from a small company with a basic understanding of IP to a significant commercial stage pharmaceutical company with a strong patent portfolio, and this would not have been possible without Boult’s support. Boult has been with us from the beginning, and we see them as not just a contractor, but an active partner to our success.”
In Wonderland v Cybex, the UPC Düsseldorf Local Division adopted The Hague's four-step approach to infringement by equivalence, marking a step towards greater UPC harmonisation.
Inside the Patagonia v. PATTIE GONIA trademark battle: How a high-profile federal lawsuit in California exposes the high-stakes clash between brand protection, identity and modern social media.
In partnership with The Sutton Trust, Boult delivered its latest Pathways programmes, giving students practical insight into IP careers, professional skills and university pathways.
The EPO Enlarged Board of Appeal will consider key questions in G 1/26 on claim interpretation, the role of the description and the assessment of added subject matter under Article 123(2) EPC.
